With a street-high upside potential of 109.4%, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) ranks among the 10 best robotics ...

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.45 per share a year ago.

This surgical robotics firm develops minimally invasive systems for urologic procedures, targeting hospitals and specialty ...

Despite a notable revenue increase and improved gross margins, PROCEPT BioRobotics Corp (PRCT) faces challenges with increased net losses and operational disruptions.

Investors in PROCEPT BioRobotics Corp (Symbol: PRCT) saw new options begin trading this week, for the July 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to ...

PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

PROCEPT BioRobotics Corp. Annual stock financials by MarketWatch. View the latest PRCT financial statements, income statements and financial ratios.

NEW YORK, March 18, 2026 /PRNewswire/ -- Procept BioRobotics (NASDAQ: PRCT) guided investors toward $325.5 million in full-year 2025 revenue -- representing 45% growth -- then delivered $308.1 million ...

NEW YORK, April 1, 2026 /PRNewswire/ -- Investors in Procept BioRobotics (NASDAQ: PRCT) lost more than 15% of their investment value after the Company disclosed financial results that diverged sharply ...

PROCEPT BioRobotics Corp. Annual stock financials by MarketWatch. View the latest PRCT financial statements, income statements and financial ratios.